February 13, 2017
Anavex appoints Peter Donhauser to its Board
Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, has appointed Peter Donhauser, D.O. to its Board of Directors.